Protective Effect of N-acetylcysteine Against From Ototoxicity

TC Erciyes University

Status and phase

Completed

Phase 3

Phase 2

Conditions

Hearing Loss, Extreme

Treatments

Drug: N-acetylcysteine

Study type

Interventional

Funder types

Other

Identifiers

NCT01271088

EUTF 2010/32

Details and patient eligibility

About

Peritonitis is currently one of the leading complications of continuous ambulatory peritoneal dialysis (CAPD). Aminoglycosides and vancomycin are used in the treatment of CAPD peritonitis despite their potential risk for ototoxicity. NAC is a molecule used in the treatment and prophylaxis of many diseases related to oxidative stress. The aim of this study was to examine whether ototoxicity due to antibiotics used in the treatment of CAPD peritonitis can be prevented by N-acetylcysteine

Full description

NAC, a thiol-containing antioxidant because of this,we want to investigate antioxidant status.

Enrollment

60 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

End-stage renal disease
Undergoing continuous ambulatory peritoneal dialysis as a renal replacement therapy
Developing the first continuous ambulatory peritoneal dialysis related peritonitis episode

Exclusion criteria

Being treated with aminoglycoside antibiotics and vancomycine within the previous 3 months
Detection of mechanical occlusion of external ear
Having signs of disturbed integrity of tympanic membrane on otoscopy or tympanometry
History of a continuous ambulatory peritoneal dialysis related peritonitis